zelicapavir

Phase 2Small molecule

EEnanta Pharmaceuticals, Inc

zelicapavir is one of 3 small molecule programs targeting RSV Infection. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

RSV InfectionRecruiting

RSV InfectionPhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in RSV Infection

#DrugCompanyPhaseTrials

Rsvpref

Pfizer

Phase 3

1 2

Obeldesivir

Gilead

Phase 2

1 3

zelicapavir

EEnanta Pharmaceuticals, Inc

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

RSV Infection

NCT07482657

Clinical

Trials by Indication[1]

Adult1 trial

A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults

Completed·EEnanta Pharmaceuticals, Inc·Phase 1·NCT06601192·72 enrolled

RSV Infection1 trial

Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zelicapavir in Participants ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus

Recruiting·EEnanta Pharmaceuticals, Inc·Phase 2·NCT07482657·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for zelicapavir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — zelicapavir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for zelicapavir. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Enanta Pharmaceuticals, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEnanta Pharmaceuticals, Inc

zelicapavir

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Adult1 trial

RSV Infection1 trial

References

Drug Info

Quick Facts

Related News